Cell and Gene Therapy (CGT) is a major breakthrough in medical science. Since penicillin, the world’s first antibiotic, was discovered in 1928, there has been measured progress in the development of new medicines. With the innovation inherent in being able to modify cells to treat or cure diseases, one of the biggest challenges today for U.S. biopharma companies during these early years for CGT is finding robust, repeatable and scalable ways to manufacture these life-saving products and test to ensure they are safe and effective therapies.  Setting up a European operation can help American biopharma companies speed up their reach as a next step in medical care and get these advanced treatments to a wide patient population.